CD274 and non-small cell lung carcinoma: According to the National Comprehensive Cancer Network (NCCN) guidelines, the recommended first-line treatment for advanced wild-type NSCLC with PD-L1 expression levels ≥ 50% is the single agent pembrolizumab.